Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomised, placebo-controlled, double-blind, parallel-group study on the efficacy and safety of WF10 and its main constituents in patients with refractory allergic rhinitis

X
Trial Profile

A multi-centre, randomised, placebo-controlled, double-blind, parallel-group study on the efficacy and safety of WF10 and its main constituents in patients with refractory allergic rhinitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WF 10 (Primary)
  • Indications Allergic rhinitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms 2014 WF10 Trial
  • Sponsors Nuvo Research
  • Most Recent Events

    • 08 Jun 2015 Results published in a Nuvo Research media release.
    • 08 Jun 2015 Status changed from active, no longer recruiting to completed according to a Nuvo Research media release.
    • 05 Mar 2015 Top-line results discussed in Nuvo Research media release and compared with results of the 2010 trial; unblinded follow-up will continue for 24 weeks post-treatment.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top